BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 3665188)

  • 1. Normal natural killer cell activity in Hodgkin's disease patients in remission.
    Douer D; Shaked N; Ramot B
    Clin Exp Immunol; 1987 Sep; 69(3):660-7. PubMed ID: 3665188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease.
    Jezewska E; Björkholm M; Giscombe R; Holm G; Tullgren O
    Clin Exp Immunol; 1985 Jul; 61(1):96-102. PubMed ID: 4042422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer (NK) activity in patients with Hodgkin's disease before, during and after multiple-agent therapy.
    Frydecka I; Kotlarek-Haus S; Kuliszkiewicz-Janus M; Kuliczkowski K
    Arch Immunol Ther Exp (Warsz); 1990; 38(5-6):407-14. PubMed ID: 2130805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer activity in spleens and lymph nodes from patients with Hodgkin's disease.
    Ruco LP; Procopio A; Uccini S; Marcorelli E; Baroni CD
    Cancer Res; 1982 May; 42(5):2063-8. PubMed ID: 6175405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon enhanced natural killer function in Hodgkin's disease.
    Levy S; Reins F; Aleksijevic A; Giron C; Oberling F; Mayer S; Lang JM
    Nouv Rev Fr Hematol (1978); 1986; 28(5):323-5. PubMed ID: 3808943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell alterations correlate with loss of renal function and dialysis duration in uraemic patients.
    Vacher-Coponat H; Brunet C; Lyonnet L; Bonnet E; Loundou A; Sampol J; Moal V; Dussol B; Brunet P; Berland Y; Dignat-George F; Paul P
    Nephrol Dial Transplant; 2008 Apr; 23(4):1406-14. PubMed ID: 18029366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating t-lymphocytes.
    Matchett KM; Huang AT; Kremer WB
    J Clin Invest; 1973 Aug; 52(8):1908-17. PubMed ID: 4541673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer activity and antibody-dependent cellular cytotoxicity in patients with non-Hodgkin's lymphoma.
    Metha BA; Advani SH; Nadkarni SJ
    Neoplasma; 1988; 35(1):61-8. PubMed ID: 3352838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cell numbers and cytotoxic activity in pediatric Hodgkin disease.
    Ikincioğullari A; Doğu F; Babacan E; Oflaz G; Ertem U; Yavuz G; Unal E; Gözdaşoğlu S; Taçyildiz N; Dağdemir A; Cavdar AO
    Pediatr Hematol Oncol; 2000 Mar; 17(2):133-9. PubMed ID: 10734655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent T4-positive cells with cytolytic activity in spleens of patients with Hodgkin's disease (a clonal analysis).
    Maggi E; Parronchi P; Del Prete G; Ricci M; Bosi A; Moretta L; Romagnani S
    J Immunol; 1986 Feb; 136(4):1516-20. PubMed ID: 3080527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of sera of breast cancer patients on NK cell activity].
    Konjević G; Spuzić I
    Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes.
    Hillinger SM; Herzig GP
    J Clin Invest; 1978 Jun; 61(6):1620-7. PubMed ID: 149140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
    Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
    Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased number of functionally defective large granular lymphocytes in lymphoma patients.
    Muhonen T; Teerenhovi L; Saksela E
    Nat Immun Cell Growth Regul; 1987; 6(2):57-64. PubMed ID: 3600676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of peripheral blood lymphocyte stimulation on zeta chain expression and IL-2 production in Hodgkin's disease.
    Frydecka I; Boćko D; Kosmaczewska A; Ciszak L; Morilla R
    Br J Cancer; 2001 May; 84(10):1339-43. PubMed ID: 11355944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption.
    Laso FJ; Madruga JI; Girón JA; López A; Ciudad J; San Miguel JF; Alvarez-Mon M; Orfao A
    Hepatology; 1997 May; 25(5):1096-100. PubMed ID: 9141423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic activity of lymphocytes from patients with Hodgkin's disease.
    Holm G; Björkholm M; Mellstedt H; Johansson B
    Clin Exp Immunol; 1975 Sep; 21(3):376-83. PubMed ID: 1081933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological characterization of Hodgkin's and non-Hodgkin's lymphoma patients with high antibody titers against Epstein-Barr virus-associated antigens.
    Masucci G; Mellstedt H; Masucci MG; Szigeti R; Ernberg I; Björkholm M; Tsukuda K; Henle G; Henle W; Pearson G
    Cancer Res; 1984 Mar; 44(3):1288-300. PubMed ID: 6318984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer activity and NK cytotoxic factors in peripheral blood and lymph node cells from non-Hodgkin's lymphoma patients.
    Nadkarni JJ; Mehta BA; Koppikar SB; Soman CS; Shrikhande SS; Advani SH
    Neoplasma; 1989; 36(6):701-8. PubMed ID: 2615873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficient natural killer cell activity in alcoholic cirrhosis.
    Charpentier B; Franco D; Paci L; Charra M; Martin B; Vuitton D; Fries D
    Clin Exp Immunol; 1984 Oct; 58(1):107-15. PubMed ID: 6236915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.